New member of the Scientific Advisory Board

We are proud to share the next member in the CarboHyde family, joining our excellent experts on the Advisory Board. Ákos Lőrincz has a complementary experience in physiology and immunology; we all respect and need to advance our pipeline most efficiently. 

Ákos is an Assistant Professor at Semmelweis University, Institute of Physiology, and a practicing cardiologist. His scientific interest is the biology of extracellular vesicles, particularly the formation of immune cell-derived extracellular vesicles and their role in immune communication. He is also convinced that the general goal of basic research is to acquire knowledge that can be applied in clinical work; therefore, he is intensively studying these vesicles’ diagnostic and therapeutic potential.

Related to carbohydrates, the surface of cellular and subcellular biological structures (e.g., extracellular vesicles) is covered with carbohydrates. The role of the glycocalyx in the formation and addressing of vesicles has already been demonstrated. In his research, He is looking for the answer to whether media with different carbohydrate compositions can increase the stability of storage-sensitive vesicle structures.

Welcome on board, Ákos!

New pipeline asset

CarboHyde announces the development of a new pipeline asset in an undisclosed partnership: we will work on the optimization, scale-up, and industrialization of a novel, carbohydrate-based non-viral gene delivery system which provided promising results in proof-of-concept preclinical studies. We expect the technology to be widely compatible with different oligonucleotides and become a safer alternative to currently used LNPs.

International cyclodextrin Symposium

The cyclodextrin event of the year is around the corner with world-class speakers from all around the globe delivering talks on all kinds of topics related to our favorite sugars.

Tamas Sohajda from our advisory board talks about cyclodextrins as antiviral agents and drug delivery systems.

We hope to see many new faces there too!

Check out the schedule here: https://www.ismn.cnr.it/ics20/pdf/ICS_program_rev.2022_5_7.pdf

CLN3 is required for the clearance of glycerophosphodiesters from lysosomes

A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford UniversityThe National Institutes of HealthLeibniz Institute on Aging – Fritz Lipmann Institute (FLI)Ludwig-Maximilians-Universität MünchenWhitehead Institute for Biomedical ResearchUniversity of Virginia School of Medicine and David Sabatini!

Full article on nature.com

carbohyde blog, rare disease